Vibe Bio
resources
Case study: Orphan Therapeutics
How Orphan Therapeutics Accelerator is optimizing rare disease search & eval
Learn how Orphan Therapeutics Accelerator uses Vibe Bio for rare disease due diligence, pipeline and competitive analysis, and in-licensing strategy.
Webinar: Watch on-demand
The AI buying guide for BD&L executives
The AI buying guide for Business Development & Licensing (BD&L) executives Webinar on-demand Evaluate & choose AI solutions to achieve real results Your biopharma BD&L teams are under unprecedented pressure…
Additional resources
Chinese biotechs & assets, a Q&A with Kanya Rajangam, MD, PhD
Recently, I had a conversation with Dr. Kanya Rajangam, to discuss current perceptions about Chinese biotech, opportunities, language challenges, and risks.
The Great Disruption: how Chinese assets will reshape drug development
Chinese biopharma companies are at an inflection point, with rapid advances in science, know-how, and talent; these assets will reshape drug development.
5 insights from JPM 2025
Based on JPM 2025, it’s safe to say that the biotech industry is experiencing a broad resurgence, with subtle yet significant disruption beneath the surface.
No posts
No posts
Whitepaper: The AI buying guide for BD&L executives
AI is already transforming how leading organizations identify, evaluate, and close deals, but not all AI platforms are built for BD&L.
No posts
No posts
No posts
Uncover new possibilities with VibeOne
Learn how VibeOne can help you discover your next indication or identify high potential development opportunities in your portfolio.